Fig. 3From: Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life dataProportion of patients with ≥50% reduction in headache days during each three-month treatment cycle compared with the 3 months prior to initiation of treatment with onabotulinumtoxin ABack to article page